Camson Biotechnologies reports standalone Revenue of Rs.

1,226 Lakhs;
EBITDA margin of 24%
Standalone Performance Highlights
Net Sales of Rs. 1,226 Lakhs
EBITDA of Rs. 289 Lakhs; Margins at 24%
Bangalore, India, November 14, 2015 Camson Biotechnologies Limited (Camson Biotech
or the Company), India's first integrated IPR driven agricultural biotechnology company,
announces its standalone Q2 and Half Year results for FY2016.
Update on the Demerger of the Seeds business: Camson Biotech submitted an application
under clause 24(f) of the listing agreement to the Bombay Stock Exchange which was duly
approved by the same vide its letter dated 30th January, 2015. Subsequently, the Scheme of
Arrangement was approved by the Honourable High Court of Karnataka vide its order dated
July 31st, 2015. The Appointed Date of the Scheme of Arrangement is April 1 st, 2014 and the
Scheme has become effective from September 1st, 2015. Post filing of the Court order with
the office of the Registrars of Companies, Camson Biotech has set the record date for the
demerger as September 21st, 2015. This is defined for the purpose of entitlement of shares of
Camson Seeds Limited (Camson Seeds), which is to be listed separately in due course.
Camson Biotechs shareholders will receive one equity share in Camson Seeds for every equity
share owned in Camson Biotech.
Consequently, the Company now operates in a single segment, i.e. Agri-Biotech. Q2 FY2016
results have been presented for the Agri-Biotech business and the results relating to previous
quarter/period/year are not comparable.
Q2 FY2016 Performance: Standalone revenue during Q2 FY2016 was Rs. 1,226 lakh at a Gross
Margin of 77%. EBITDA during the quarter was Rs. 289 lakhs with a 24% margin. This quarter
performance was undermined by the erratic and below normal monsoon which dampened
the sentiment of the farmer community.
Recent Corporate Developments:

Camson Biotech introduced Calphomil in the Ginger segment in Kerala and Karnataka.
Caltem, Calrrhiza and Calbahar products have been introduced for the Banana crop in
UP. These represent significant wins given the large markets and crop segments.

The Company signed a MoU with Zuari Agri Sciences. Under the MoU, Zuari will market
Zero Residue biocides products manufactured by Camson Biotech. The arrangement
1|Page

brings out the best of both companies. While, Camson Biotech will leverage its
technological and R&D firepower, Zuari will use its wide distribution network to market
these products and spread the message of Zero Residue Cultivation across all sections of
the farming community.

Camson Biotech filed patents for its discovery of Natural Fertilizer, a product which is
derived from microbial extracts. This is a breakthrough step wherein Natural Fertilizer has
the capacity to replace synthetic fertilizer throughout the world. Being a clean technology
it also addresses the concerns about the toxicity, safety and the environment issues facing
the world.

Commenting the business and performance, Mr. Santosh Nair, CEO of Camson
Biotechnologies Limited said:
Q2 FY2016 has been a very challenging period for the Indian agriculture industry due the
erratic and below normal monsoon resulting in a drought like situation, particularly in
southern India. While the season started well with reasonable rainfall in July-Aug but later
during the season dried up. Due to the deficient monsoon, crop acreage and yields have been
impacted putting a lot of pressure on the industry. This also had an impact on our top line.
However, due to the managements ongoing focus on product mix rationalisation and cost
optimisation initiatives, we managed to sustain the margin profile.
On the operational front, we introduced our products in the key large markets and crop
segments. This is a testament to the quality of our products and the strength of our marketing
network. Our recent MoU with Zuari opens up an avenue to cover the broader market with
our products through an institutional channel. We believe that such efforts and partnering
together would not only add momentum but also go a long way in propagating the zero
residue farming concept in the country.
Overall, we are confident of our R&D prowess and product portfolio. Furthermore, after the
demerger of Seeds business, we now have a much focused approach for our Biocides business
and look forward to an exciting growth for the Company.

2|Page

About Camson:
Camson Bio Technologies Limited (Camson or the Company) is India's first integrated IPR
driven agricultural biotechnology company. Founded in 1993, Camson is headquartered in
Bangalore, with primary focus on biotech R&D. The Company is a pioneer in zero residue
farming products, which uses secondary metabolites (biological origin) of microbes to kill /
inhibit pathogens, with no use of chemicals. It has been recognized by Deloitte as one the
fastest growing technology companies in 2015 and conferred the Technology Fast 500 award
and awarded the Leaders of Tomorrow Award by ET Now & Indiamart 2014-15.

Contact Details:
Camson Bio Technologies Limited (CIN: L85110KA1993PLC014944)
C-7, 7th Floor, Corporate Block, Golden Enclave, Old Airport Road, Bangalore - 560 017
Santosh R Nair
Camson Bio Technologies
Saket Somani
Churchgate Partners

info@camsonbiotechnologies.com
+91 80 4076 8900
Camson@churchgatepartnersindia.com
+91 22 6169 5988

Safe Harbor:
This release contains statements that contain forward looking statements including, but
without limitation, statements relating to the implementation of strategic initiatives, and
other statements relating to Camson Biotechs future business developments and economic
performance. While these forward looking statements indicate our assessment and future
expectations concerning the development of our business, a number of risks, uncertainties and
other unknown factors could cause actual developments and results to differ materially from
our expectations. These factors include, but are not limited to, general market, macroeconomic, governmental and regulatory trends, movements in currency exchange and interest
rates, competitive pressures, technological developments, changes in the financial conditions
of third parties dealing with us, legislative developments, and other key factors that could
affect our business and financial performance. Camson Biotech undertakes no obligation to
publicly revise any forward looking statements to reflect future / likely events or circumstances.

3|Page